NASDAQ · Biotechnology

Greenwich LifeSciences, Inc. (GLSI) Stock

$16.53 +9.18% NASDAQ: GLSI Healthcare

Valuation

MetricValue
Price$16.53
Market Cap$242.63M
P/E Ratio-11.03
P/B Ratio79.65
P/S Ratio0.00
EPS (TTM)$-1.21
52-Week High$34.10
52-Week Low$7.78
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-793.76%
ROA-244.25%
ROCE-701.55%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-5.0M$-8.0M$-9.0M$-18.0M$-19.0M
Net Profit$-5.0M$-8.0M$-9.0M$-17.0M$-19.0M
EPS$-0.35$-0.61$-0.69$-1.21$-1.43
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$27.0M$13.0M$7.0M$4.0M$6.0M
Total Liabilities$0$0$0$3.0M$6.0M
Cash$27.0M$13.0M$7.0M$4.0M$6.0M
Borrowings$0$0$0$0$0

Latest News

Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial MT Newswires · Jul 16, 2026 Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 GlobeNewswire · Jul 16, 2026 Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday MT Newswires · Jul 9, 2026 Sector Update: Healthcare MT Newswires · Jul 9, 2026 Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 GlobeNewswire · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-6.0M$-6.0M$-7.0M$-10.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$-8.0M$0$0$0
Net Cash Flow$-1.0M$-14.0M$-6.0M$-3.0M$2.0M
Free Cash Flow$-4.0M$-6.0M$-6.0M$-7.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.84
EV / EBITDA-11.09
FCF Yield-5.01%
Quick Ratio1.54
Interest Coverage0.00
Return 1Y75.86%
Return 3Y103.53%
Return 5Y-54.65%

Ownership

Insiders Held47.86%
Institutions Held12.48%
Institutions Float Held23.93%
Institutional HolderSharesReport Date
Blackrock Inc.433,8602026-03-31
Vanguard Capital Management LLC298,2662026-03-31
Geode Capital Management, LLC155,4662026-03-31
State Street Corporation133,8752026-03-31
Nuveen, LLC88,7172026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGENAgenus Inc. $7.67 +1.72% 3.66 $319.40M 0.00%
ATOSAtossa Therapeutics, Inc. $2.44 +0.83% -0.54 $24.34M 0.00%
CGTXCognition Therapeutics, Inc. $0.88 -2.04% -4.82 $78.48M 0.00%
HURATuHURA Biosciences, Inc. $1.96 +1.55% -3.46 $124.82M 0.00%
IMMXImmix Biopharma, Inc. $9.46 +1.83% -11.00 $514.64M 0.00%

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. is led by CEO Snehal S. Patel, employs 4 people, headquartered in US, publicly traded since 2020.

Greenwich LifeSciences, Inc. (GLSI) stock trades at $16.53 with a market capitalization of $242.63M. The stock is valued at a price-to-earnings (P/E) ratio of -11.03, price-to-book of 79.65, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.78 and $34.10, and currently trades 51.5% below its 52-week high.

On profitability, Greenwich LifeSciences, Inc. generates a return on equity (ROE) of -793.76%, return on capital employed of -701.55%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides